For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Vyndamax and Tafamidis meglumine represents a genuine change. These innovative therapies stabilize the transthyretin protein, slowing its harmful build-up and reducing the severity of the illness. Individuals are now reporting improve